Daan Gene Past Earnings Performance
Past criteria checks 0/6
Daan Gene has been growing earnings at an average annual rate of 20.7%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 19.1% per year.
Key information
20.7%
Earnings growth rate
20.7%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | 19.1% |
Return on equity | -3.7% |
Net Margin | -28.4% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?
May 02Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 05Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)
Mar 25Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Mar 06Revenue & Expenses BreakdownBeta
How Daan Gene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1,038 | -295 | 468 | 282 |
31 Dec 23 | 1,181 | 105 | 442 | 302 |
30 Sep 23 | 3,553 | 854 | 896 | 494 |
30 Jun 23 | 5,906 | 2,221 | 1,060 | 585 |
31 Mar 23 | 9,025 | 3,769 | 1,148 | 659 |
01 Jan 23 | 12,046 | 5,412 | 1,543 | 702 |
30 Sep 22 | 11,363 | 6,004 | 1,182 | 669 |
30 Jun 22 | 10,858 | 5,615 | 1,281 | 594 |
31 Mar 22 | 8,687 | 4,170 | 1,345 | 568 |
01 Jan 22 | 7,664 | 3,618 | 1,255 | 509 |
30 Sep 21 | 7,419 | 3,436 | 1,383 | 329 |
30 Jun 21 | 6,691 | 3,268 | 1,167 | 273 |
31 Mar 21 | 7,092 | 3,391 | 1,350 | 200 |
31 Dec 20 | 5,341 | 2,449 | 1,034 | 167 |
30 Sep 20 | 3,890 | 1,549 | 989 | 148 |
30 Jun 20 | 2,715 | 810 | 914 | 135 |
31 Mar 20 | 1,435 | 250 | 559 | 105 |
31 Dec 19 | 1,098 | 92 | 524 | 95 |
30 Sep 19 | 1,060 | 103 | 341 | 88 |
30 Jun 19 | 1,190 | 103 | 344 | 96 |
31 Mar 19 | 1,343 | 102 | 386 | 95 |
31 Dec 18 | 1,479 | 102 | 425 | 99 |
30 Sep 18 | 1,575 | 89 | 465 | 86 |
30 Jun 18 | 1,575 | 88 | 426 | 132 |
31 Mar 18 | 1,581 | 88 | 449 | 114 |
31 Dec 17 | 1,542 | 87 | 478 | 92 |
30 Sep 17 | 1,609 | 98 | 510 | 73 |
30 Jun 17 | 1,594 | 101 | 570 | 0 |
31 Mar 17 | 1,627 | 107 | 582 | 0 |
31 Dec 16 | 1,613 | 107 | 565 | 0 |
30 Sep 16 | 1,638 | 107 | 503 | 0 |
30 Jun 16 | 1,636 | 105 | 495 | 0 |
31 Mar 16 | 1,536 | 102 | 462 | 0 |
31 Dec 15 | 1,474 | 101 | 439 | 0 |
30 Sep 15 | 1,322 | 133 | 398 | 0 |
30 Jun 15 | 1,223 | 153 | 363 | 0 |
31 Mar 15 | 1,150 | 153 | 349 | 0 |
31 Dec 14 | 1,086 | 153 | 338 | 0 |
30 Sep 14 | 1,016 | 123 | 330 | 0 |
30 Jun 14 | 964 | 147 | 344 | 0 |
31 Mar 14 | 903 | 145 | 319 | 0 |
31 Dec 13 | 854 | 144 | 317 | 0 |
30 Sep 13 | 759 | 148 | 326 | 0 |
30 Jun 13 | 702 | 109 | 303 | 0 |
Quality Earnings: 002030 is currently unprofitable.
Growing Profit Margin: 002030 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002030 is unprofitable, but has reduced losses over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare 002030's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002030 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 002030 has a negative Return on Equity (-3.72%), as it is currently unprofitable.